[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201691376A1 - Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака - Google Patents

Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака

Info

Publication number
EA201691376A1
EA201691376A1 EA201691376A EA201691376A EA201691376A1 EA 201691376 A1 EA201691376 A1 EA 201691376A1 EA 201691376 A EA201691376 A EA 201691376A EA 201691376 A EA201691376 A EA 201691376A EA 201691376 A1 EA201691376 A1 EA 201691376A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonist
combination
vegfr inhibitor
cancer treatment
combination therapies
Prior art date
Application number
EA201691376A
Other languages
English (en)
Inventor
Жан-Франсуа Андрэ Мартини
Джамал Кристо Тарази
Родолфо Флёри Перини
Дэвид Дж. Мауро
Original Assignee
Пфайзер Инк.
Мерк Шарп Энд Домэ Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52463238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691376(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Инк., Мерк Шарп Энд Домэ Корп. filed Critical Пфайзер Инк.
Publication of EA201691376A1 publication Critical patent/EA201691376A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем изобретении описываются комбинированные терапии, включающие антагонист рецептора программируемой смерти клеток 1 (PD-1) и ингибитор VEGFR, и применение комбинированных терапий для лечения рака и, в частности, для лечения рака, который экспрессирует PD-L1.
EA201691376A 2014-02-04 2015-02-03 Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака EA201691376A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935809P 2014-02-04 2014-02-04
PCT/US2015/014212 WO2015119930A1 (en) 2014-02-04 2015-02-03 Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
EA201691376A1 true EA201691376A1 (ru) 2017-01-30

Family

ID=52463238

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691376A EA201691376A1 (ru) 2014-02-04 2015-02-03 Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака

Country Status (22)

Country Link
US (3) US10570202B2 (ru)
EP (3) EP3102605B1 (ru)
JP (3) JP6591428B2 (ru)
KR (2) KR20230023810A (ru)
CN (2) CN105960415A (ru)
AU (1) AU2015214390B2 (ru)
BR (1) BR112016017256A2 (ru)
CA (2) CA3210360A1 (ru)
CY (2) CY1121374T1 (ru)
DK (1) DK3102605T3 (ru)
EA (1) EA201691376A1 (ru)
ES (2) ES2710211T3 (ru)
HU (2) HUE041469T2 (ru)
IL (2) IL311399A (ru)
MX (1) MX2016010082A (ru)
PL (2) PL3498734T3 (ru)
PT (2) PT3498734T (ru)
SG (2) SG10201806656UA (ru)
SI (2) SI3498734T1 (ru)
TR (1) TR201901507T4 (ru)
TW (1) TWI663983B (ru)
WO (1) WO2015119930A1 (ru)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP3079699A4 (en) * 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
UA119659C2 (uk) 2013-12-12 2019-07-25 Шанхай Хенжуй Фармасьютикал Ко., Лтд. Антитіло до pd-1, його антигензв'язуючий фрагмент та їхнє медичне застосування
SI3498734T1 (sl) * 2014-02-04 2022-02-28 Pfizer Inc. Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka
EP3102604B1 (en) 2014-02-04 2020-01-15 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
WO2015134605A1 (en) * 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
SG10201810615VA (en) 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US11326211B2 (en) 2015-04-17 2022-05-10 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to PD-1 antagonists
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CN105669864B (zh) * 2015-12-23 2018-10-16 杭州尚健生物技术有限公司 抗人程序性死亡受体1抗体及其制备方法和用途
CN107126563B (zh) * 2016-02-26 2021-09-10 博生吉医药科技(苏州)有限公司 含低剂量阻断vegf信号通路的抗体的组合物及其用途
RU2018146886A (ru) * 2016-06-10 2020-07-10 Новартис Аг Пути терапевтического применения ингибитора c-raf
WO2018044888A1 (en) * 2016-08-29 2018-03-08 Chen James C Tumor vaccination systems, devices, and methods
EP3515495A4 (en) * 2016-09-26 2020-08-26 Ensemble Group Holdings METHOD OF EVALUATION AND TREATMENT OF CANCER IN HUMANS WITH DYSREGULATED LYMPHATIC SYSTEMS
EP3515940A1 (en) * 2016-09-26 2019-07-31 ImClone LLC Combination therapy for cancer
CN109843324A (zh) 2016-10-06 2019-06-04 辉瑞公司 用于治疗癌症的avelumab用药方案
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN117586401A (zh) 2017-01-20 2024-02-23 大有华夏生物医药集团有限公司 抗pd-1抗体及其用途
AU2018228873A1 (en) * 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3592382A1 (en) * 2017-03-06 2020-01-15 Merck Patent GmbH Aqueous anti-pd-l1 antibody formulation
EP3600426A4 (en) * 2017-03-31 2021-01-20 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN ANTI-CTLA4 ANTIBODY
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
MX2019013751A (es) 2017-05-16 2020-01-15 Jiangsu Hengrui Medicine Co Composicion farmaceutica de anticuerpos del ligando 1 de muerte programada y su uso.
CN117899212A (zh) 2017-06-02 2024-04-19 拜耳医药保健有限责任公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN119285770A (zh) * 2017-08-09 2025-01-10 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
JP7341130B2 (ja) * 2017-09-29 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 癌を治療するための組成物および治療方法
BR112020006371A2 (pt) * 2017-10-13 2020-09-29 Merck Patent Gmbh combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1
CA3077664A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TW201922793A (zh) * 2017-11-16 2019-06-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US20200095322A1 (en) * 2018-06-20 2020-03-26 Incyte Corporation Anti-pd-1 antibodies and uses thereof
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
MX2021000558A (es) 2018-07-18 2021-04-13 Genentech Inc Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
CN112424231B (zh) * 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
MX2021004348A (es) 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
CN114340679A (zh) * 2018-10-31 2022-04-12 基因泰克公司 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
EP3876934A4 (en) * 2018-11-05 2022-08-03 Aveo Pharmaceuticals, Inc. USE OF TIVOZANIB TO TREAT PEOPLE WITH REFRACTORY CANCER
WO2020093993A1 (zh) * 2018-11-06 2020-05-14 江苏恒瑞医药股份有限公司 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途
CN113710702A (zh) 2019-01-14 2021-11-26 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use
CR20220207A (es) 2019-11-13 2022-06-06 Genentech Inc Compuestos terapéuticos y métodos de uso
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
AU2021244485B2 (en) 2020-03-25 2024-05-16 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
EP4173636A4 (en) 2020-06-30 2024-08-28 Shionogi & Co., Ltd Combined use of anti-ccr8 antibody and chemotherapeutic agent
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US20230321074A1 (en) 2020-09-09 2023-10-12 Shenzhen Chipscreen Biosciences, Co., Ltd. Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
EP4240492A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022098628A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
WO2022098648A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
JP2023551906A (ja) 2020-12-02 2023-12-13 ジェネンテック， インコーポレイテッド ネオアジュバントおよびアジュバント尿路上皮癌腫療法のための方法および組成物
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
WO2022247846A1 (zh) * 2021-05-26 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
EP4377350A2 (en) 2021-07-28 2024-06-05 Genentech, Inc. Methods and compositions for treating cancer
CN117715936A (zh) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 用于治疗癌症的方法和组合物
CA3227334A1 (en) * 2021-07-28 2023-02-02 Tiumbio Co., Ltd. Pharmaceutical composition for preventing or treating tumor, and use thereof
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
TW202340212A (zh) 2021-11-24 2023-10-16 美商建南德克公司 治療性化合物及其使用方法
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
WO2023134787A2 (zh) * 2022-01-14 2023-07-20 上海君实生物医药科技股份有限公司 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
KR20230131448A (ko) * 2022-03-04 2023-09-13 주식회사 파노로스바이오사이언스 VEGF-Grab 및 PD-1 또는 PD-L1 길항제를 포함하는 병용 투여용 조성물
CN119487067A (zh) 2022-04-01 2025-02-18 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
TW202417042A (zh) 2022-07-13 2024-05-01 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
CN119604530A (zh) 2022-07-19 2025-03-11 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025002264A1 (zh) * 2023-06-30 2025-01-02 默沙东有限责任公司 包含偶联物的药物组合的治疗方法和用途
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US6778740B2 (en) * 2002-07-31 2004-08-17 Agilent Technologies, Inc. Alignment of optical fiber elements
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
AU2004226586B2 (en) * 2003-04-03 2008-12-11 Pfizer Inc. Dosage forms comprising AG013736
WO2006048751A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
KR20070058690A (ko) 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조방법
EP1809625A1 (en) 2004-11-02 2007-07-25 Pfizer, Inc. Methods for preparing indazole compounds
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
CN101094836A (zh) 2004-11-02 2007-12-26 辉瑞大药厂 制备吲唑化合物的方法
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2608952A1 (en) 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
PT2134702T (pt) 2007-04-05 2017-07-31 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-(piridin-2-il)etenil]indazol adequadas para o tratamento de crescimento celular anormal em mamíferos
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP4331604B1 (en) 2008-12-09 2025-03-05 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
TWI654994B (zh) 2011-08-01 2019-04-01 建南德克公司 利用ｐｄ－１軸結合拮抗劑及ｍｅｋ抑制劑治療癌症之方法
AU2012313885A1 (en) 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide
EP2776031A1 (en) 2011-11-11 2014-09-17 Pfizer Inc N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
MX376235B (es) 2012-05-04 2025-03-07 Pfizer Inc Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014163684A1 (en) 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CN108464981B (zh) 2013-11-07 2022-06-24 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
RS59659B2 (sr) 2013-12-17 2023-08-31 Hoffmann La Roche Postupci lečenjа raka pomoću аntаgonistа koji vežu osovinu pd-1 i pomoću tаksаnа
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SI3498734T1 (sl) 2014-02-04 2022-02-28 Pfizer Inc. Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka
CA2942039A1 (en) 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
WO2015134605A1 (en) 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2017513942A (ja) 2014-04-11 2017-06-01 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Ｍｅｒｔｋ特異的ピロロピリミジン化合物
US20170158776A1 (en) 2014-05-15 2017-06-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
CN107001478B (zh) 2014-10-14 2022-01-11 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
JP2020007359A (ja) 2020-01-16
PT3102605T (pt) 2019-02-12
CY1124785T1 (el) 2022-11-25
ES2899457T3 (es) 2022-03-11
JP2017506227A (ja) 2017-03-02
US20220324979A1 (en) 2022-10-13
MX2016010082A (es) 2016-10-07
EP3498734A1 (en) 2019-06-19
AU2015214390B2 (en) 2020-05-07
NZ722296A (en) 2023-09-29
US20170166641A1 (en) 2017-06-15
US20200325228A1 (en) 2020-10-15
US10570202B2 (en) 2020-02-25
SG11201605824XA (en) 2016-08-30
EP3971209A1 (en) 2022-03-23
ES2710211T3 (es) 2019-04-23
JP2021130709A (ja) 2021-09-09
BR112016017256A2 (pt) 2017-10-17
SI3498734T1 (sl) 2022-02-28
TWI663983B (zh) 2019-07-01
HUE057205T2 (hu) 2022-04-28
PT3498734T (pt) 2021-12-06
SI3102605T1 (sl) 2019-04-30
CA2937521C (en) 2023-08-29
TR201901507T4 (tr) 2019-02-21
WO2015119930A1 (en) 2015-08-13
JP6894952B2 (ja) 2021-06-30
AU2015214390A1 (en) 2016-08-04
TW201615212A (zh) 2016-05-01
DK3102605T3 (en) 2019-02-25
CA3210360A1 (en) 2015-08-13
IL311399A (en) 2024-05-01
JP6591428B2 (ja) 2019-10-16
CA2937521A1 (en) 2015-08-13
EP3102605A1 (en) 2016-12-14
KR20160108566A (ko) 2016-09-19
CN118286440A (zh) 2024-07-05
SG10201806656UA (en) 2018-09-27
PL3498734T3 (pl) 2022-02-14
EP3102605B1 (en) 2018-11-14
EP3498734B1 (en) 2021-09-01
IL246760A0 (en) 2016-08-31
CN105960415A (zh) 2016-09-21
HUE041469T2 (hu) 2019-05-28
CY1121374T1 (el) 2020-05-29
KR20230023810A (ko) 2023-02-17
PL3102605T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
EA201691376A1 (ru) Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
PH12016501550A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
MX2022001447A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
MY195110A (en) Antibodies to PD-1 and uses Thereof
IL254131B (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
MX2017000857A (es) Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
NZ731467A (en) Anti-tim3 antibodies and methods of use
NZ724691A (en) Quinoline derivatives as smo inhibitors
PH12021552158A1 (en) Antibodies to icos
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
EA201791133A1 (ru) Ингибиторы erk
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
TW201713333A (en) Methods of treating a neurodegenerative disease
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).